Etracker Debug:
	et_pagename = "Clinical Chemistry and Laboratory Medicine (CCLM)|cclm|C|[EN]"
Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

13 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition



Application of proteomics to prenatal screening and diagnosis for aneuploidies

Chan-Kyung J. Cho1, 2 / 1–3, ,

1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

2Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada

3Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada

Corresponding author: Dr. Eleftherios P. Diamandis, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 6th Floor, Room 6-201, Box 32, 60 Murray Street, Toronto, ON M57 3L9, Canada Phone: +1 416-586-8443, Fax: +1 416-619-5521

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 1, Pages 33–41, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2011.002, October 2010

Publication History

Published Online:


Current screening for fetal aneuploidies relies on biochemical and ultrasound measurements, and the sensitivity and specificity needs to be improved to reduce the number of pregnant women subjected to invasive diagnostic procedures, such as amniocentesis. Proteomic technologies enable new strategies for discovering biomarkers from complex biological fluids in a high-throughput and sensitive manner. Since mass spectrometry-based techniques allow for both qualitative and quantitative analysis of a given proteome, they have been widely used to resolve and compare the proteome of maternal plasma, serum, urine, cervical-vaginal fluid, and amniotic fluid. Comparisons of proteomes of normal fluids with those from aneuploidy pregnancies have revealed a host of candidate markers that still need to be verified. In parallel with proteomics, there is interest in other emerging techniques, such as RNA-SNP analysis or quantitation of fetal DNA by shotgun sequencing. Although these genomic techniques hold much promise, discovery of additional markers via quantitative proteomic comparisons could drastically improve current conventional screening at reasonable cost. Proteomics-based biomarker discovery is applicable to detection of not just aneuploidies, but also other pregnancy-related diseases.

Keywords: aneuploidy; biomarker discovery; Down syndrome; mass spectrometry; prenatal screening; proteomics

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.